Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom

References

• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 1978; 193: 1007–1008
   Web of Science ®Google Scholar
• Smith KA. Interleukin-2: Inception, impact and implications. Science 1988; 240: 1169–1176
   PubMed Web of Science ®Google Scholar
• Grimm EA, Mazumder A, Zhang HZ, et al. The lymphokine-activated killer cell phenomenon: lysis of NK-resistant fresh solid tumor cells by IL-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–1841
   PubMed Web of Science ®Google Scholar
• Grimm EA, Robb RJ, Roth JA, et al. Lymphokine-activated killer cell (LAK) phenomenon III. Evidence that IL-2 alone is sufficient for direct activation of PBL into LAK. J Exp Med 1983; 158: 1356–1361
   PubMed Web of Science ®Google Scholar
• Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986; 164: 814–825
   PubMed Web of Science ®Google Scholar
• Mulé JJ, Shu S, Schwarz SL, et al. Adoptive immunotherapy of established metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–1489
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Mulé JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2. J Exp Med 1985; 161: 1169–1188
   PubMed Web of Science ®Google Scholar
• Lafreniere R, Rosenberg SA. Successful immunotherapy of experiemental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2. Cancer Res 1985; 45: 3735–3741
   PubMed Web of Science ®Google Scholar
• Thompson JA, Peace DJ, Klarnet JP, et al. Eradication of disseminated murine leukemia by treatment with high-dose interleukin-2. J Immunol 1986; 137: 3675–3680
   PubMed Web of Science ®Google Scholar
• Mulé JJ, Yang JC, Lafreniere RL, et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by systemic administration of high-dose recombinant interleukin-2. J Immunol 1987; 139: 285–294
   PubMed Web of Science ®Google Scholar
• Weber JS, Kay G, Tanaka K, et al. Immunotherapy of a murine tumor with interleukin-2 increased sensitivity after MHC class I gene transfection. J Exp Med 1987; 166: 1716–1735
   PubMed Web of Science ®Google Scholar
• Fomi G, Giovarelli M, Santoni A, et al. Interleukin-2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol 1987; 138: 4033–4041
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Schwarz SL, Spiess PL. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin 2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 1988; 80: 1393–1397
   PubMed Web of Science ®Google Scholar
• Peace DJ, Cheever MA. Toxicity and therapeutic efficacy of high dose interleukin-2. In vivo infusion antibody to NK attenuates toxicity without compromising efficacy against murine-leukemias. J Exp Med 1989; 169: 161–173
   PubMed Web of Science ®Google Scholar
• Mulé JJ., Yang J, Shu S, et al. The anti-tumor efficacy of lymphokine activated killer cells and recombinant interleukin-2 in vivo: Direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 1986; 136: 3899–3909
   PubMed Web of Science ®Google Scholar
• Bubenik J, Indrova M. The anti-tumor efficacy of human recombinant interleukin-2. Correlation between sensitivity of tumours of the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo. Cancer Immunol Immunother 1987; 24: 269–271
   PubMed Web of Science ®Google Scholar
• Allavena P, Scala G, Djeu JY, et al. Production of multiple cytokines by clones of human large granular lymphocytes. Cancer Immunol Immunother 1985; 19: 121–126
   PubMed Web of Science ®Google Scholar
• Wiltrout RH, Mace K, Young HA, et al. Cytokine involvement in combined modality approaches to the treatment of murine cancer (abstr). Fed. Proc. 1989; 669
   Google Scholar
• Hiserodt JC, Schwarz RE. LAK cells: molecules, cells and mechanisms involved in their antitumor activity (abstr). Fed Proc 1989; 669
   Google Scholar
• Dvorak HF, Gresser I. Microvascular injury in the pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989; 81: 497–502
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Galli SJ, Dvorak AM. Cellular and vascular manifestations of cell-mediated immunity. Hum Pathol 1986; 17: 122–137
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• Lotze MT, Chang AE, Seipp CA, et al. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. J Am Med Assoc 1986; 256: 3117–3124
   PubMed Web of Science ®Google Scholar
• West WH, Tauer KW, Yannelli JR, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905
   PubMed Web of Science ®Google Scholar
• Wang J, Walle A, Gordon B, et al. Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2 activated autologous leukocytes and continuous infusions of low dose interleukin-2. Am J Med 1987; 83: 1016–1023
   PubMed Web of Science ®Google Scholar
• Schoof DD, Gramolini BA, Davidson DL, et al. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine activated killer cells. Cancer Res 1988; 48: 5007–5010
   PubMed Web of Science ®Google Scholar
• Fisher RI, Coltman CA, Doroshow JH, et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Int Med 1988; 108: 518–523
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7: 477–485
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patietns with metastatic cancer. N Engl J Med 1985; 313: 1485–1492
   PubMed Web of Science ®Google Scholar
• Sondel PM, Kohler PC, Hank JA, et al. Recombinant interleukin-2 given by repetitive weekly cycles in patients with cancer: clinical and immunological effects. Cancer Res 1988; 48: 2561–2567
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kohler PC, Hank JA, et al. Repetitive weeldy cycles of interleukin-2: II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 1988; 80: 1451–1461
   PubMed Web of Science ®Google Scholar
• Thompson JA, Lee DJ, Lindgren CG, et al. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol 1988; 6: 669–678
   PubMed Web of Science ®Google Scholar
• Allison MAK, Jones SE, McGuffey P. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia and selected solid tumors. J Clin Oncol 1989; 7: 75–80
   PubMed Web of Science ®Google Scholar
• Creekmore SP, Harris JE, Ellis TM, et al. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. J Clin Oncol 1989; 7: 276–284
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kohler PC, Hank JA, et al. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst 1988; 80: 60–64
   PubMed Web of Science ®Google Scholar
• Hank JA, Kohler PC, Hillman GW, et al. In vivo induction of the lymphokine-activated killer phenomenon interleukin-2 (IL-2) dependent human lymphokine activated killer (LAK) cells generated in vivo during administration of human recombinant IL-2. Cancer Res 1988; 48: 1965–1972
   PubMed Web of Science ®Google Scholar
• Goldstein D, Sosman JA, Hank JA, et al. Repetitive weekly cycles of interleukin-2 (IL-2): the effect of outpatient treatment with a lower dose of IL-2 on non-MHC restricted killer activity. Cancer Res 1989; 49: 6832–6839
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech R, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• Hercend T, Griffin JD, Bensussan A, et al. Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associate antigens NKHIA and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest 1985; 75: 932–943
   PubMed Web of Science ®Google Scholar
• Pross HF, Maroun JA. The standardization of NK cell assays for use in studies of biological response modifiers. J Immunol Methods 1985; 68: 235–249
   Web of Science ®Google Scholar
• Strack van Schyndel RJM, Voerman HJ, Golding RP, et al. Interleukin-2 therapy and blockage of double-lumen catheters. Lancet 1989; 1: 962–963
   Web of Science ®Google Scholar
• Phillips JH, Gemlo BT, Myers WW, et al. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 1987; 5: 1933–1941
   PubMed Web of Science ®Google Scholar
• McMannis JD, Fisher RI, Creekmore SP, et al. In vivo effects of recombinant IL-2. I. Isolation of circulating leu19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol 1988; 140: 1335–1340
   PubMed Web of Science ®Google Scholar
• Hillman GW, Fisch P, Prieve AF, et al. LAK activity induced by in vivo IL-2 therapy: a predominant role for lymphocytes with increased expression of CD2 and Leu19, but negative for CD16 antigen. Cancer Res 1989; 49: 3680–3688
   PubMed Web of Science ®Google Scholar
• Lotze MT, Custer MC, Sharrow SO, et al. In vivo administration of purified interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors follow interleukin-2 administration. Cancer Res 1987; 47: 2188–2195
   PubMed Web of Science ®Google Scholar
• Voss SD, Hank JA, Nobis CA, et al. Serum interleukin-2 receptor levels during IL-2 therapy reflects systemic lymphoid mass activation. Cancer Immunol Immunother 1989; 29: 261–269
   PubMed Web of Science ®Google Scholar
• Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine-activated killer cells and recombinant interleukin-2 can mediate the regression of both immunogenic and non-immunogenic sarcomas and adenocarcinoma. J Immunol 1985; 135: 4273–4280
   PubMed Web of Science ®Google Scholar
• Klarnet JP, Matis LA, Kern DE, et al. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. J Immunol 1987; 138: 4012–4107
   PubMed Web of Science ®Google Scholar
• Mier JW, Vachino G, Van der Mear J, et al. Induction of circulating tumor necrosis factor as the mechanism for the febrile response to interleukin-2 in cancer patients. J Clin Immunol 1988; 8: 426–436
   PubMed Web of Science ®Google Scholar
• Gemlo BT, Palladino MA, Jaffe HS, et al. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 1988; 48: 5864–5867
   PubMed Web of Science ®Google Scholar
• Ettinghausen SE, Puri RK, Rosenberg SA. Increased vascular permeability in organs mediated by systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 1988; 80: 177–188
   PubMed Web of Science ®Google Scholar
• Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors. Analysis of toxicity and management guidelines. J Clin Oncol 1989; 7: 486–498
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer using interleukin-2. Ann Int Med 1988; 108: 853–864
   PubMed Web of Science ®Google Scholar
• Moertel CG. On lymphokines, cytokines and breakthroughs. J Med Assoc 1986; 256: 3141
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Cancer therapy with interleukin-2: Immunologic manipulations can mediate the regression of cancer in humans. J Clin Oncol 1988; 6: 403–406
   PubMed Web of Science ®Google Scholar
• Atkins MB, Gould JA, Allegretta M, et al. Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol 1986; 4: 1380–1391
   PubMed Web of Science ®Google Scholar
• Thompson JA, Lee DJ, Lindgren CG, et al. Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine-activated killer cells. Cancer Res 1989; 49: 235–240
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Kempf RA, Harel W, et al. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 1988; 6: 409–425
   PubMed Web of Science ®Google Scholar
• Krigel RL, Padavic-Shaller KA, Rudolph AR, et al. A phase I study of recombinant interleukin-2 plus recombinant β-interferon. Cancer Res 1988; 48: 3875–3881
   PubMed Web of Science ®Google Scholar
• Dillman RO, Barth N, Oldham RK, et al. Continuous interleukin-2 (IL-2) and lymphokine activated killer (LAK) cells in advanced cancer (abstr). Proc Am Soc Clin Oncol 1989; 8: A730
   Google Scholar
• Boldt DH, Mills BJ, Gemlo BT, et al. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine activated killer cells in humans. Cancer Res 1988; 48: 4409–4416
   PubMed Web of Science ®Google Scholar
• Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Parkinson DR. Interleukin-2 in cancer therapy. Sem Oncol 1988; 15: 10–26
   PubMed Web of Science ®Google Scholar
• Bradley EC, de Groat S, Doyle LV, et al. LAK induction in vivo in patients treated with interleukin-2 may be necessary for tumor regression (abstr). Proc Am Assoc Cancer Res 1987; 28: A405
   Web of Science ®Google Scholar
• Bradley EC, Louie AC, Paradise CM, et al. Antitumor response in patients with metastatic renal cell carcinoma is dependent upon regimen intensity (abstr). Proc Am Soc Clin Oncol 1989; 8: A519
   Google Scholar
• Anderson TM, Ibayashi Y, Tokuda Y. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine killer activity of human tumor infiltrating lymphocytes. Cancer Res 1988; 48: 1180–1183
   PubMed Web of Science ®Google Scholar
• Cotran RS, Pober JS, Gimbrone MA, et al. Endothelial activation during interleukin 2 immunotherapy: a possible mechanism for the vascular leak syndrome. J Immunol 1987; 139: 1883–1888
   Google Scholar
• Agah R, Malloy B, Sherrod A, et al. Successful therapy of natural killer-resistant pulmonary metastases by the synergism of γ-interferon with tumor necrosis factor and interleukin-2. Cancer Res 1988; 48: 2245–2248
   PubMed Web of Science ®Google Scholar
• McIntosh JK, Mulé JJ, Merino MJ, et al. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and a recombinant tumor necrosis factor-α. Cancer Res 1988; 48: 4011–4017
   PubMed Web of Science ®Google Scholar
• Cameron RB, McIntosh JK, Rosenberg SA. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 1988; 48: 5810–5187
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Spiess P, Lafreiniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318–1321
   PubMed Web of Science ®Google Scholar
• Itoh K, Tilden AB, Balch CM. Interleukin-2 activation of cytotoxic T-lymphocytes infiltrating human metastatic melanomas. Cancer Res 1986; 46: 3011–3017
   PubMed Web of Science ®Google Scholar
• Muul LM, Spiess PJ, Director EP, et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138: 989–995
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Muul LM, Rosenberg SA. Interleukin-2 expanded tumor infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988; 48: 206–214
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988; 319: 1676–1680
   PubMed Web of Science ®Google Scholar
• Cohen PJ, Lotze MT, Roberts RJ. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2: correlation of response with T cell infiltration and HLA-DR expression. Am J Pathol 1987; 129: 208–216
   PubMed Web of Science ®Google Scholar
• Foon KA. Biological response modifiers: the new immunotherapy. Cancer Res 1989; 49: 1621–1639
   PubMed Web of Science ®Google Scholar
• Papa MZ, Yang JC, Vetto JC, et al. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 1988; 48: 122–129
   PubMed Web of Science ®Google Scholar
• Kawase I, Komuta K, Hara H, et al. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin-2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res 1988; 48: 1173–1179
   PubMed Web of Science ®Google Scholar
• Philip T, Stofer G, Jogmin C, et al. Recombinant human interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the European experience (abstr). Proc Soc Clin Oncol 1989; 8: A507
   Google Scholar
• Weiss GR, Margolin K, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection IL-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma (abstr). Proc Am Soc Clin Oncol 1989; 8: A509
   Google Scholar
• Hawkins MJ. IL-2/LAK: Current status and possible future directions. Cancer, Principles and Practice of Oncology Update, VT. DeVita, S. Hellman, SA. Rosenberg. Lippincott, Philadelphia 1989; Vol 3: 8, 1–14
   Google Scholar
• Marshall ME, Batter K, Dickson L, et al. Treatment of metastatic renal cell carcinoma with ‘low dose’ interleukin-2 and lymphokine activated killer cells (abstr). Proc Am Soc Clin Oncol 1989; 8: A525
   Google Scholar
• Bukowski RM, Goodman P, Crawford ED, et al. Phase II evaluation of recombinant interleukin-2 in metastatic renal cell carcinoma: SWOG 8617 (abstr). Proc Am Soc Clin Oncol 1989; 8: A556
   Google Scholar
• Smith J, Clark J, Steis R, et al. Interleukin-2 and lymphokine activated killer cell therapy: Analysis of two different regimens (abstr). Proc Am Soc Clin Oncol 1989; 8: A708
   Google Scholar
• Thompson J, Lee D, Benz L, et al. High dose continuous intravenous infusion interleukin-2 and lymphokine-activated killer cell therapy for renal cell carcinoma and melanoma (abstr). Proc Am Soc Clin Oncol 1989; 8: A704
   Google Scholar